AC Vaccine Platform


AVAX has developed a proprietary Autologous Cell (AC) Vaccine® Platform, a therapy that stimulates a patients’ immune system to combat their cancer cells.  It utilizes a vaccine consisting of patients’ own (autologous) cancer cells, which comprise all of the relevant tumor rejection antigens while eliminating the need to identify any of them.

Each patient’s own cancer contains all of the antigens to which a destructive immune response could be directed.  So, autologous tumor cells are the most logical basis for a therapeutic vaccine.  The actual “rejection” antigens do not have to be identified or characterized, an effort that could require vast amounts of time and money, especially if those antigens are different for each cancer patient.  AVAX Technologies, Inc. is a pioneer in personalized cancer vaccines. Historically, and still, the challenge in developing an effective treatment for cancer has been determining the appropriate tumor antigens to target.  AVAX’s technology utilizes the most relevant antigens for targeting – the patient’s own tumor cells, termed ‘autologous cells’ (“AC”).  The patient’s own tumor cells are chemically modified through the process of haptenization which results in each tumor antigen on the cells’ surface becoming visible to the patient’s immune system.  These modified tumor cells are injected back into the patient in order to stimulate an attack by the immune system and destroy the patient’s cancer cells.

The Autologous Cell Vaccine Technology Platform (“AC Vaccine”) is a universal platform approach to personalized cancer vaccine therapy. The overall process is illustrated below:


Vaccines are a unique class of pharmaceutical products that can either be preventative or therapeutic.  AVAX’s cancer vaccines are designed to be therapeutic. Although subject to the same United States Food and Drug Administration (US FDA) regulations as other biological products, vaccines are inherently more difficult to develop, characterize, and manufacture than most pharmaceutical products. Vaccine development and commercialization is a long complex process. Stringent regulatory pre-requisites must be achieved throughout development for a vaccine to be considered for licensure.


AC VACCINE – Key Features

  • Autologous, intact cells, best source of tumor antigens. Each patient’s tumor antigens are unique and heterogeneous
  • Platform approach amenable to any cancer that is resectable.
  • Platform process is amenable to bio-engineered next generation vaccine product pipeline
  • Modified with a hapten or bio-engineered antigenic proteins increases immunogenicity of vaccine
  • Frozen, longer shelf life, minimizes contamination, maximizes geographical market compared to fresh/live.